Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NACompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

March 31, 2011

Conditions
Pancreatic Cancer
Interventions
BIOLOGICAL

Cetuximab

Cetuximab: an initial loading dose of 400 mg/m2 will be given followed by 250 mg/m2 administered weekly. Cetuximab will be given first followed by gemcitabine on the weeks the patient receives cytotoxic chemotherapy on day 1. Cetuximab will be given as a single agent on Day 8. The treatment will be given on two-week cycles.

DRUG

Gemcitabine Hydrochloride

Gemcitabine 1000 mg/m2 IV day 1. The treatment will be given on two-week cycles.

DRUG

Oxaliplatin

Oxaliplatin 100 mg/m2 IV day 2. The treatment will be given on two-week cycles.

Trial Locations (1)

33136

University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami

All Listed Sponsors
lead

University of Miami

OTHER

NCT00448838 - Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter